Replique has reached a cooperation agreement with the biotechnology company Repertoire to jointly develop autologous immunotherapy for autoimmune diseases.

On January 29th, the biotechnology company Repertoire announced a strategic partnership with Eli Lilly and Company to jointly develop tolerogenic therapies for a variety of autoimmune diseases. The collaboration aims to develop treatment options that can restore immune homeostasis, allowing patients to achieve long-term relief from their diseases without the systemic immune suppression commonly seen with current therapies. Under the agreement, Repertoire will receive an initial payment of $85 million and up to an additional $1.84 billion based on achieving specific research and commercial milestones, as well as tiered royalties based on net sales.